1-3 of 3
Nabeel Rajeh, MD
Close
Sort by
Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 566.
https://doi.org/10.1182/blood-2019-131676
Published: 2019
Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 230.
https://doi.org/10.1182/blood-2018-99-119259
Published: 2018
Journal Articles

Surviving Stem Cell Transplantation Program In War Time In Syria

Nabeel Rajeh, MD, Maha Manchi, Seham Suliman, Zahera Fahed, Muhamad Barali, Muhamad Kalta
Journal: Blood
Blood (2013) 122 (21): 5525.
https://doi.org/10.1182/blood.V122.21.5525.5525
Published: 2013